Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F13/00—Bandages or dressings; Absorbent pads
  • A61F13/02—Adhesive bandages or dressings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
  • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
  • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
  • A61K9/7061—Polyacrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L15/225—Mixtures of macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/44—Medicaments
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/48—Surfactants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/58—Adhesives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
  • A61P23/02—Local anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Definitions

• the stratum corneum is a lipophilic barrier that limits drug uptake.
• One of the most effective physical methods for reducing the barrier function of the stratum corneum is the occlusion, which is used in virtually every systemic transdermal system. The occlusion is achieved by the occlusion.
• Foils of polyethylene or polypropylene As polymers or pressure-sensitive adhesive with low water vapor permeability z. As polyisobutylene or block polymers of styrene and butadiene or styrene and isoprene used.
• non-steroidal anti-inflammatory drugs have a size that corresponds to the area of the area to be treated, and thus a size that to increase the wearing comfort a certain elasticity of the
• Stretchability or elasticity are often textile for such patches
• WO 01/91718 A2 describes a two-phase matrix in which an active-ingredient-containing polyacrylate phase is dispersed in an outer, self-adhesive formulation based on polyisobutylene or styrene-butadiene-styrene block polymers.
• the disadvantage here is that the occlusion effect in practical layer thicknesses is always maximum and the outer phase, as stated above, very badly adheres to moist skin.
• the only advantage of such a matrix is that the active ingredient is in a polymer with a higher saturation solubility.
• Polyacrylate adhesive or silicone adhesive behave under such conditions much better, but can create by their high water vapor permeability itself no occlusive conditions. The use of polyacrylate or silicone adhesives would therefore, according to the prior art, make multi-layered matrices with layers of different composition necessary in order to complicate the manufacturing process and to increase the manufacturing price which is important for this product group.
• the solution to the problem according to the invention has been found to be a low water vapor permeable polymer such as e.g. Polyisobutylene or a block polymer of styrene and butadiene or isoprene in the one or more of the water vapor permeable pressure-sensitive adhesives built matrix layer (s)
• a low water vapor permeable polymer such as e.g. Polyisobutylene or a block polymer of styrene and butadiene or isoprene in the one or more of the water vapor permeable pressure-sensitive adhesives built matrix layer (s)
• a patch according to the invention consists of a textile backing layer, a matrix layer containing active ingredient based on polyacrylate or silicone adhesives with a water-vapor-impermeable polymer dispersed therein and a protective layer to be removed before use.
• the structure of such a patch is shown in FIG.
• the invention therefore relates to a transdermal or topical, active ingredient-containing
• Patch having a non-occlusive backing layer, a matrix formed from one or more polymer layer (s) having at least one pharmaceutically active agent in one or more of the layers, characterized in that the structure-forming base polymers of the layer or layers are not or only slightly occlusive and in at least one of the polymer layers, a second polymer which has little or no miscibility with the base polymer and is dispersed with a low water vapor permeability.
• the backing layer is preferably made of a textile material, in particular a woven or non-woven nonwoven fabric or a composite of such.
• materials come here z.
• Polyurethane is also suitable as a water-vapor-permeable sheet material.
• the structuring base polymer of the skin layer in contact with the skin is preferably a pressure-sensitive adhesive.
• Suitable pressure-sensitive adhesives are for example polyacrylate adhesive or silicone adhesive.
• the matrix is preferably constructed as a single layer.
• the polymer with low water vapor permeability can, for example
• the dispersed phase of this polymer is preferably an average particle size of 5 to 50 ⁇ m, in particular 7 to 40 ⁇ m, very particularly preferably 10 to 30 ⁇ m.
• the proportion of dispersed particles in the matrix is generally between 5 and 50 wt .-%, preferably 7 and 40 wt .-%, in particular 10 and 30 wt .-%.
• the basis weight of the matrix is generally between 50 and 400 g / m 2 , preferably between 60 and 300 g / m 2 , in particular between 70 and 200 g / m 2 .
• the active pharmaceutical ingredient may be a non-steroidal anti-inflammatory drug (NSAID for non-steroidal anti-inflammatory drug).
• NSAID for non-steroidal anti-inflammatory drug
• Active substances from the group of diclofenac or one of its pharmaceutically acceptable salts ketoprofen, ibuprofen, flurbiprofen, naproxen, tiaprofenic acid, indomethacin, piroxicam, tenoxicam, meloxicam, flufenamic acid or
• diclofenac salts are, for example, the diclofenac sodium salt, the diclofenac potassium salt, the diclofenac-diethylammonium salt or the dihydroxyethyl-pyrrolidine salt of diclofenac.
• Sorbitan fatty acid esters and dimethyl isosorbitol are also suitable.
• surface-active surfactants which can positively influence the stability of the biphasic matrix layer by reducing the interfacial energy.
• the water vapor-impermeable polymer is embedded in the matrix. It is therefore practically not in contact with the skin and therefore does not affect the adhesion of the pressure-sensitive adhesive on the skin.
• the sample composition and the measured water vapor permeability are additionally shown in Table 1 and the water vapor permeability in Figure 3.
• the water vapor permeability is then usually between 50 and
• Diclofenac sodium salt was chosen as the active ingredient and incorporated into a single-layer matrix system with a textile backing layer. Assuming that the hydrophilic active substance salt is only soluble in a negligible amount in polyisobutylene, the amount of active ingredient was chosen so that the active ingredient concentration, despite different
• Polyisobutylene content in the outer polyacrylate phase remained the same in all samples. This excludes that differences in permeation rates are due not only to different degrees of occlusion, but also to different thermodynamic activities.
• Optimum Polyisobutylenge halts at 30 wt .-%, since 40 wt .-% in about the same result as 20 wt .-% show. At higher levels, the decreasing proportion of the active substance-containing phase and the effective diffusion path, which also becomes longer for the active substance, then has a disadvantageous effect.
• polyisobutylene (Oppanol® B 10, BASF) are dissolved in 110 g of n-heptane by stirring. This results in 200 g of polyisobutylene solution having a solids content of 45% g / g. 20 g of diclofenac sodium salt are dissolved with stirring in 774 g of Duro-Tak® 387-2353 (solids content 36%), 150 g of ethyl acetate and 33 g of oleic acid. This results in 929 g of active ingredient-containing polyacrylate solution having a solids content of 34% g / g.
• the coating composition is prepared by adding the in Table 4
• the dispersions are prepared by rapid mechanical stirring at 400 rpm for 10 minutes.
• the matrices are prepared by coating these dispersions on a siliconized 100 ⁇ thick polyester film with subsequent removal of the solvent by drying for 25 minutes at 50 ° C.
• the thickness of the still solvent-containing coating film is chosen so that the dry
• Matrix film has a basis weight of 110 gl m 2 .
• the matrix to Formulation 4 is obtained by laminating the already dried matrix film to Formulation 3 once with itself.
• the dried films are laminated with a bi-elastic polyester fabric to obtain the total laminate.
• Fig. 2 Inventive patch with adjustable occlusion
• Fig. 3 Water vapor permeability as a function of the content of polyisobutylene and the thickness of the matrix layer
• FIG. 5 polyisobutylene particles dispersed in the polyacrylate adhesive phase (scale: 500: 1)

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Materials Engineering (AREA)
• Dermatology (AREA)
• Pain & Pain Management (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Emergency Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Anesthesiology (AREA)
• Biomedical Technology (AREA)
• Rheumatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Polymers & Plastics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=46924436

Family Applications (1)

Country Status (14)

Cited By (1)

Families Citing this family (6)

Citations (3)

Family Cites Families (9)

• 2011
  • 2011-09-26 DE DE102011114411A patent/DE102011114411A1/de not_active Withdrawn
• 2012
  • 2012-09-25 RU RU2014116821A patent/RU2616524C2/ru active
  • 2012-09-25 KR KR1020147011086A patent/KR101945573B1/ko not_active Expired - Fee Related
  • 2012-09-25 AU AU2012314560A patent/AU2012314560C1/en not_active Ceased
  • 2012-09-25 ES ES12762597T patent/ES2755728T3/es active Active
  • 2012-09-25 EP EP12762597.8A patent/EP2760436B1/de active Active
  • 2012-09-25 JP JP2014531268A patent/JP6033309B2/ja active Active
  • 2012-09-25 CN CN201710819641.3A patent/CN107595818A/zh active Pending
  • 2012-09-25 WO PCT/EP2012/068828 patent/WO2013045420A1/de not_active Ceased
  • 2012-09-25 BR BR112014007210-8A patent/BR112014007210B1/pt active IP Right Grant
  • 2012-09-25 CN CN201280046758.8A patent/CN103826619A/zh active Pending
  • 2012-09-25 MX MX2014003669A patent/MX338901B/es active IP Right Grant
  • 2012-09-25 IN IN2984CHN2014 patent/IN2014CN02984A/en unknown
  • 2012-09-25 US US14/346,527 patent/US9180103B2/en active Active
  • 2012-09-25 CA CA2849956A patent/CA2849956C/en active Active

Patent Citations (4)

Also Published As

Similar Documents

Legal Events